Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database

K. Petoumenos; C. Ringland; R. Goodman; M. Gotowski; D. Couldwell; L. Lewis; D. Austin; M. Block; D. Quan; A. Gowers; K.R. Brown; N. Skobalj; S. Mallal

doi:10.1111/j.1468-1293.2005.00280.x

Back

Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database

Journal article

Open access

Peer reviewed

Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database

K. Petoumenos, C. Ringland, R. Goodman, M. Gotowski, D. Couldwell, L. Lewis, D. Austin, M. Block, D. Quan, A. Gowers, …

HIV Medicine, Vol.6(3), pp.155-163

2005

DOI: https://doi.org/10.1111/j.1468-1293.2005.00280.x

Files and links (2)

pdf

antiretroviral_treatment_change.pdfDownload View

Published (Version of Record) Open Access

url

Link to Published Version *Subscription may be requiredView

Abstract

Objectives To assess the impact of highly active antiretroviral therapy (HAART) on rates of change of antiretroviral treatment among patients co-infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) in the Australian HIV Observational Database (AHOD). Methods Analysis was based on 805 of the 2218 patients recruited to the AHOD by March 2003, who had commenced HAART after 1 January 1997, who had recorded test results for HBV surface antigen and anti-HCV antibody, and who had follow-up of more than 3 months. The effect of hepatitis co-infection on the rate of antiretroviral treatment change after commencing HAART was assessed using a random-effect Poisson regression model. Results Among those included in the analyses, the prevalences of HBV and HCV were 4.8% and 12.8%, respectively. The overall rate of combination antiretroviral treatment change was 0.74 combinations per year. Factors independently associated with an increased rate of change of combination antiretroviral treatment were: prior AIDS-defining illness; prior exposure to double combination antiretroviral therapy; and antiretroviral treatment class. Co-infection with HBV and/or HCV was not found to be significantly associated with the rate of combination antiretroviral treatment change. Conclusions While both HBV and HCV co-infections are relatively common in the AHOD, they do not appear to be serious impediments to the treatment of HIV-infected patients.

Details

Title: Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database
Authors/Creators: K. Petoumenos (Author/Creator)
C. Ringland (Author/Creator)
R. Goodman (Author/Creator)
M. Gotowski (Author/Creator)
D. Couldwell (Author/Creator)
L. Lewis (Author/Creator)
D. Austin (Author/Creator)
M. Block (Author/Creator)
D. Quan (Author/Creator)
A. Gowers (Author/Creator)
K.R. Brown (Author/Creator)
N. Skobalj (Author/Creator)
S. Mallal (Author/Creator)
Publication Details: HIV Medicine, Vol.6(3), pp.155-163
Publisher: Blackwell Publishing
Identifiers: 991005541429007891
Copyright: 2005 British HIV Association
Murdoch Affiliation: Centre for Clinical Immunology and Biomedical Statistics
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

301 File views/ downloads

51 Record Views

12 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.125 Hepatitis; 1.125.83 HCV
Web Of Science research areas: Infectious Diseases
ESI research areas: Immunology